On the other hand, PD-L1 expressed in solid tumors including melanoma and carcinomas of the lung, breast, bladder, kidney, pancreas, oesophagus, and ovary is an important prognostic marker for immunotherapies that use anti-PD-L1 [54–56]. The gene discussed is CD274; the disease is carcinoma.